Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Javanshir Esfandyari"'
Autor:
Katarzyna Radke, Karin Hansson, Jonas Sjölund, Magdalena Wolska, Jenny Karlsson, Javanshir Esfandyari, Kristian Pietras, Kristina Aaltonen, David Gisselsson, Daniel Bexell
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101149- (2021)
High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.Na) in preclinical models of high-risk neuroblastoma. Among several h
Externí odkaz:
https://doaj.org/article/6744e2c17bf2479da962240e572b1b78
Autor:
Sofie Mohlin, Karin Hansson, Katarzyna Radke, Sonia Martinez, Carmen Blanco‐Apiricio, Cristian Garcia‐Ruiz, Charlotte Welinder, Javanshir Esfandyari, Michael O'Neill, Joaquin Pastor, Kristoffer von Stedingk, Daniel Bexell
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 8, Pp 1-17 (2019)
Abstract The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL‐302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL‐302 in over 700 cell lines repres
Externí odkaz:
https://doaj.org/article/940f73d202764e8eb9fccad18ef1fd8e
Autor:
Sofie Mohlin, Karin Hansson, Katarzyna Radke, Sonia Martinez, Carmen Blanco‐Aparicio, Cristian Garcia‐Ruiz, Charlotte Welinder, Javanshir Esfandyari, Michael O'Neill, Joaquin Pastor, Kristoffer von Stedingk, Daniel Bexell
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 1, Pp 1-1 (2020)
Externí odkaz:
https://doaj.org/article/45d12cad1ecf49c5889356105e3e973f
Autor:
Daniel Bexell, Sven Påhlman, David Gisselsson, Tommy Martinsson, Jan Koster, Jenny Karlsson, Rosa Noguera, Ana P. Berbegall, Javanshir Esfandyari, Siv Beckman, Anna Börjesson, Torbjörn Backman, Ingrid Øra, Karin Hansson, Jakob Willforss, Fredrik Levander, Håkan Axelson, David Lindgren, Angela Martinez-Monleon, Susanne Fransson, Kristoffer von Stedingk, Noémie Braekeveldt
Supplementary Figure S2. Related to Figure 4. Intratumor heterogeneity is less prominent than intertumor heterogeneity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4018df4322af6c9a89af7822237d8445
https://doi.org/10.1158/0008-5472.22420524.v1
https://doi.org/10.1158/0008-5472.22420524.v1
Autor:
Daniel Bexell, Sven Påhlman, David Gisselsson, Tommy Martinsson, Jan Koster, Jenny Karlsson, Rosa Noguera, Ana P. Berbegall, Javanshir Esfandyari, Siv Beckman, Anna Börjesson, Torbjörn Backman, Ingrid Øra, Karin Hansson, Jakob Willforss, Fredrik Levander, Håkan Axelson, David Lindgren, Angela Martinez-Monleon, Susanne Fransson, Kristoffer von Stedingk, Noémie Braekeveldt
Supplementary Table S6. Related to Figure 4. Top 1000 varying genes based on SD across all samples derived from Patient/PDOX #5. Supplementary Table S7. Related to Figure 4. List of enriched Gene Ontology terms by cluster derived from the gene cluste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ba8c0944323b5846ea82c083c26c41
https://doi.org/10.1158/0008-5472.22420509
https://doi.org/10.1158/0008-5472.22420509
Autor:
Daniel Bexell, Sven Påhlman, David Gisselsson, Tommy Martinsson, Jan Koster, Jenny Karlsson, Rosa Noguera, Ana P. Berbegall, Javanshir Esfandyari, Siv Beckman, Anna Börjesson, Torbjörn Backman, Ingrid Øra, Karin Hansson, Jakob Willforss, Fredrik Levander, Håkan Axelson, David Lindgren, Angela Martinez-Monleon, Susanne Fransson, Kristoffer von Stedingk, Noémie Braekeveldt
Supplementary Table S1. Related to Figure 1. List of all somatic mutations detected in patient tumors, and in PDOXs from low and high in vivo generations. Supplementary Table S2. Related to Figure 2. List of all chromosomal copy number changes in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170164e0409beb1d8df63dd22cf38554
https://doi.org/10.1158/0008-5472.22420515.v1
https://doi.org/10.1158/0008-5472.22420515.v1
Autor:
Daniel Bexell, Sven Påhlman, David Gisselsson, Tommy Martinsson, Jan Koster, Jenny Karlsson, Rosa Noguera, Ana P. Berbegall, Javanshir Esfandyari, Siv Beckman, Anna Börjesson, Torbjörn Backman, Ingrid Øra, Karin Hansson, Jakob Willforss, Fredrik Levander, Håkan Axelson, David Lindgren, Angela Martinez-Monleon, Susanne Fransson, Kristoffer von Stedingk, Noémie Braekeveldt
Patient-derived xenografts (PDX) and the Avatar, a single PDX mirroring an individual patient, are emerging tools in preclinical cancer research. However, the consequences of intratumor heterogeneity for PDX modeling of biomarkers, target identificat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54a5e6a262fb28d83691cc35be7e3650
https://doi.org/10.1158/0008-5472.c.6510675.v1
https://doi.org/10.1158/0008-5472.c.6510675.v1
Autor:
Daniel Bexell, Sven Påhlman, David Gisselsson, Tommy Martinsson, Jan Koster, Jenny Karlsson, Rosa Noguera, Ana P. Berbegall, Javanshir Esfandyari, Siv Beckman, Anna Börjesson, Torbjörn Backman, Ingrid Øra, Karin Hansson, Jakob Willforss, Fredrik Levander, Håkan Axelson, David Lindgren, Angela Martinez-Monleon, Susanne Fransson, Kristoffer von Stedingk, Noémie Braekeveldt
Supplementary methods and legends to supplementary figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5750a08efe21a2a77f0c9918797ade09
https://doi.org/10.1158/0008-5472.22420518
https://doi.org/10.1158/0008-5472.22420518
Autor:
Adriana, Mañas, Kristina, Aaltonen, Natalie, Andersson, Karin, Hansson, Aleksandra, Adamska, Alexandra, Seger, Hiroaki, Yasui, Hilda, van den Bos, Katarzyna, Radke, Javanshir, Esfandyari, Madhura Satish, Bhave, Jenny, Karlsson, Diana, Spierings, Floris, Foijer, David, Gisselsson, Daniel, Bexell
Publikováno v:
Science advances. 8(43)
Chemotherapy resistance and relapses are common in high-risk neuroblastoma (NB). Here, we developed a clinically relevant in vivo treatment protocol mimicking the first-line five-chemotherapy treatment regimen of high-risk NB and applied this protoco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::73c1b02cad822cd0f4d0fd0ec0e9c5fe
https://pubmed.ncbi.nlm.nih.gov/36306349
https://pubmed.ncbi.nlm.nih.gov/36306349
Autor:
Daniel Bexell, Kristina Aaltonen, Katarzyna Radke, Kristian Pietras, Karin M Hansson, Jenny Karlsson, Javanshir Esfandyari, Magdalena Wolska, Jonas Sjölund, David Gisselsson
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 8, Pp 101149-(2021)
Translational Oncology, Vol 14, Iss 8, Pp 101149-(2021)
Highlights • Analysis of multiple tumor types reveal neuroblastoma sensitivity to rigosertib. • Neuroblastoma 2D and 3D organoid models are sensitive to rigosertib. • Rigosertib causes G2M cell cycle arrest rather than inhibition of Ras binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30381ab25f3309025a4e3f7310dec952
http://europepmc.org/articles/PMC8207190
http://europepmc.org/articles/PMC8207190